Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21072260 | 1.00 | MGAM (0.43) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL1284525 | 1.00 | MGAM (0.43) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL2721040 | 0.92 | — | — | |
| SCHEMBL30415874 | 0.91 | ALDH1A1 (0.38) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL14389976 | 0.86 | MGAM (0.44) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL14389978 | 0.86 | MGAM (0.44) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL18971858 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL7782689 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL1721997 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2JAK2 | |
| SCHEMBL3036111 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230107793-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-8557797-B2 | Triazolopyridine derivatives and their therapeutic use | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| EP-2398798-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094956-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED. (GB) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | MGAM 4770/4885GAA 4853/4885SI 4755/4885 |
| US-20230107793-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MGAM 2763/4885GAA 1113/4885SI 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.